Express Scripts Holding Co (NASDAQ:ESRX) Director Mahon Thomas P. Mac sold 5,234 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $99.50, for a total value of $520,783.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of NASDAQ ESRX traded down $0.84 during trading on Friday, reaching $98.48. The company had a trading volume of 3,386,770 shares, compared to its average volume of 3,248,175. Express Scripts Holding Co has a 12 month low of $59.17 and a 12 month high of $100.43. The firm has a market capitalization of $56.09 billion, a PE ratio of 13.87, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. The company has a current ratio of 0.77, a quick ratio of 0.65 and a debt-to-equity ratio of 0.63.
Express Scripts (NASDAQ:ESRX) last announced its earnings results on Wednesday, October 31st. The company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.42 by $0.01. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The company had revenue of $25.56 billion for the quarter, compared to analyst estimates of $25.11 billion. During the same quarter in the prior year, the company earned $2.51 EPS. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, analysts forecast that Express Scripts Holding Co will post 9.08 earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on ESRX shares. BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Credit Suisse Group lowered Express Scripts from an “outperform” rating to a “neutral” rating and upped their price target for the company from $90.00 to $96.50 in a research report on Tuesday, September 18th. ValuEngine upgraded Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. Royal Bank of Canada upped their price target on Express Scripts to $94.00 and gave the company an “outperform” rating in a research report on Monday, August 27th. Finally, Mizuho set a $101.00 price target on Express Scripts and gave the company a “hold” rating in a research report on Monday, November 5th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Express Scripts currently has an average rating of “Hold” and a consensus target price of $89.07.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Recommended Story: Trading Strategy
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.